On Tuesday, July 21, 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the world's first lower-carbon metered-dose inhaler for asthma patients. The new versions of Clenil Modulite (beclometasone) inhalers use a more environmentally friendly propellant, HFA-152a, reducing carbon emissions by up to 90% compared to current inhalers.
Impact on Asthma Patients
Over 7 million people in the UK have asthma, one of the most common long-term conditions. The new inhalers contain the same active ingredient, beclometasone dipropionate, a corticosteroid that reduces airway inflammation to prevent symptoms and flare-ups. Dosages and therapeutic uses remain unchanged, ensuring patients can continue their usual medication while lowering their environmental impact.
Next-Generation Propellant
The MHRA's approval is the first globally for pressurised metered-dose inhalers (pMDIs) using HFA-152a propellant. This propellant is not a medicine but delivers the inhaled medication effectively. The updated inhalers are set to launch in the UK in 2026; until then, current Clenil Modulite inhalers remain available.
Regulatory and Safety Details
Julian Beach, MHRA Executive Director of Healthcare Quality and Access, stated: "Keeping patients safe and enabling their access to high-quality, safe and effective medicines are key priorities for us. This approval marks the world's first authorisation of an inhaler using the next-generation propellant HFA-152a. It demonstrates how innovation can support both patient care and environmental sustainability while maintaining the high standards of quality, safety and effectiveness patients expect." The MHRA will continue to monitor safety and effectiveness closely.
Side Effects and Monitoring
Common side effects of beclometasone inhalers include oral thrush, hoarseness, and throat irritation. A complete list will be available in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) upon release. A government statement noted: "As with any medicine, the MHRA will keep the safety and effectiveness of beclometasone dipropionate under close review. Anyone who suspects they are experiencing a side effect should speak to their doctor, pharmacist or nurse and report it directly through the Yellow Card scheme or via the MHRA Yellow Card app."
